169 related articles for article (PubMed ID: 20128596)
1. Synthesis and biological evaluation of polysulfated oligosaccharide glycosides as inhibitors of angiogenesis and tumor growth.
Johnstone KD; Karoli T; Liu L; Dredge K; Copeman E; Li CP; Davis K; Hammond E; Bytheway I; Kostewicz E; Chiu FC; Shackleford DM; Charman SA; Charman WN; Harenberg J; Gonda TJ; Ferro V
J Med Chem; 2010 Feb; 53(4):1686-99. PubMed ID: 20128596
[TBL] [Abstract][Full Text] [Related]
2. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis.
Ferro V; Dredge K; Liu L; Hammond E; Bytheway I; Li C; Johnstone K; Karoli T; Davis K; Copeman E; Gautam A
Semin Thromb Hemost; 2007 Jul; 33(5):557-68. PubMed ID: 17629854
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, biological activity, and preliminary pharmacokinetic evaluation of analogues of a phosphosulfomannan angiogenesis inhibitor (PI-88).
Karoli T; Liu L; Fairweather JK; Hammond E; Li CP; Cochran S; Bergefall K; Trybala E; Addison RS; Ferro V
J Med Chem; 2005 Dec; 48(26):8229-36. PubMed ID: 16366604
[TBL] [Abstract][Full Text] [Related]
4. Discovery of PG545: a highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis.
Ferro V; Liu L; Johnstone KD; Wimmer N; Karoli T; Handley P; Rowley J; Dredge K; Li CP; Hammond E; Davis K; Sarimaa L; Harenberg J; Bytheway I
J Med Chem; 2012 Apr; 55(8):3804-13. PubMed ID: 22458531
[TBL] [Abstract][Full Text] [Related]
5. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: design, synthesis, and optimization of pharmacokinetics and biological activities.
Haviv F; Bradley MF; Kalvin DM; Schneider AJ; Davidson DJ; Majest SM; McKay LM; Haskell CJ; Bell RL; Nguyen B; Marsh KC; Surber BW; Uchic JT; Ferrero J; Wang YC; Leal J; Record RD; Hodde J; Badylak SF; Lesniewski RR; Henkin J
J Med Chem; 2005 Apr; 48(8):2838-46. PubMed ID: 15828822
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and heparanase inhibitory activity of sulfated mannooligosaccharides related to the antiangiogenic agent PI-88.
Fairweather JK; Hammond E; Johnstone KD; Ferro V
Bioorg Med Chem; 2008 Jan; 16(2):699-709. PubMed ID: 17967543
[TBL] [Abstract][Full Text] [Related]
7. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors.
Hagedorn M; Zilberberg L; Wilting J; Canron X; Carrabba G; Giussani C; Pluderi M; Bello L; Bikfalvi A
Cancer Res; 2002 Dec; 62(23):6884-90. PubMed ID: 12460903
[TBL] [Abstract][Full Text] [Related]
8. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
9. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
10. Sulfated malto-oligosaccharides bind to basic FGF, inhibit endothelial cell proliferation, and disrupt endothelial cell tube formation.
Foxall C; Wei Z; Schaefer ME; Casabonne M; Fugedi P; Peto C; Castellot JJ; Brandley BK
J Cell Physiol; 1996 Sep; 168(3):657-67. PubMed ID: 8816920
[TBL] [Abstract][Full Text] [Related]
11. Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity.
Parish CR; Freeman C; Brown KJ; Francis DJ; Cowden WB
Cancer Res; 1999 Jul; 59(14):3433-41. PubMed ID: 10416607
[TBL] [Abstract][Full Text] [Related]
12. VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo.
Ueda Y; Yamagishi T; Ikeya H; Hirayama N; Itokawa T; Aozuka Y; Samata K; Nakaike S; Tanaka M; Ono M; Saiki I
Anticancer Res; 2004; 24(5A):3009-17. PubMed ID: 15517909
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
Ferguson D; Rodriguez LE; Palma JP; Refici M; Jarvis K; O'Connor J; Sullivan GM; Frost D; Marsh K; Bauch J; Zhang H; Lin NH; Rosenberg S; Sham HL; Joseph IB
Clin Cancer Res; 2005 Apr; 11(8):3045-54. PubMed ID: 15837760
[TBL] [Abstract][Full Text] [Related]
14. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
15. HSulf-1 inhibits angiogenesis and tumorigenesis in vivo.
Narita K; Staub J; Chien J; Meyer K; Bauer M; Friedl A; Ramakrishnan S; Shridhar V
Cancer Res; 2006 Jun; 66(12):6025-32. PubMed ID: 16778174
[TBL] [Abstract][Full Text] [Related]
16. A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer.
Joyce JA; Freeman C; Meyer-Morse N; Parish CR; Hanahan D
Oncogene; 2005 Jun; 24(25):4037-51. PubMed ID: 15806157
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of tumor metastasis by heparanase inhibiting species of heparin.
Vlodavsky I; Mohsen M; Lider O; Svahn CM; Ekre HP; Vigoda M; Ishai-Michaeli R; Peretz T
Invasion Metastasis; 1994-1995; 14(1-6):290-302. PubMed ID: 7657522
[TBL] [Abstract][Full Text] [Related]
18. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic activity of Andrographis paniculata extract and andrographolide.
Sheeja K; Guruvayoorappan C; Kuttan G
Int Immunopharmacol; 2007 Feb; 7(2):211-21. PubMed ID: 17178389
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of B16-BL6 melanoma lung colonies by semisynthetic sulfaminoheparosan sulfates from E. coli K5 polysaccharide.
Poggi A; Rossi C; Casella N; Bruno C; Sturiale L; Dossi C; Naggi A
Semin Thromb Hemost; 2002 Aug; 28(4):383-92. PubMed ID: 12244486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
